Fast track approvals for low risk edits

Introduction

Fast-track approvals for low-risk edits refer to simplified regulatory procedures designed to accelerate the assessment and authorisation of genetically edited organisms that are considered to present minimal environmental, agricultural or public health risks. Advances in genome-editing technologies, particularly CRISPR-Cas systems, have made it possible to introduce precise genetic changes into plants, animals and microorganisms.

Some genome-editing techniques produce genetic modifications that could also occur naturally or through conventional breeding. Such modifications may not involve the introduction of foreign genetic material. Consequently, several countries have introduced simplified regulatory pathways for certain low-risk genome-edited products.

The purpose of fast-track approval is to encourage scientific innovation, reduce unnecessary regulatory delays and support agricultural productivity while maintaining appropriate biosafety standards. However, determining whether a genetic edit is genuinely low-risk remains an important legal and scientific challenge.

Meaning and objectives of fast-track approvals

Fast-track approval is a regulatory mechanism through which eligible biotechnology products receive simplified assessment, reduced documentation requirements or quicker administrative decisions compared with conventional genetically modified organisms.

The main objectives include:

Accelerating the development of agricultural biotechnology.

Reducing unnecessary regulatory costs.

Encouraging research and commercial investment.

Promoting climate-resilient and disease-resistant crops.

Supporting innovation in genome-editing technologies.

Maintaining environmental and food safety.

Establishing proportionate regulation based on scientific risk.

Meaning of low-risk genome edits

Low-risk genome edits generally refer to genetic modifications that are considered unlikely to create significant new biological or environmental hazards.

Examples may include:

Small targeted deletions in existing genetic material.

Minor changes involving one or a few DNA sequences.

Genetic modifications that do not introduce foreign DNA.

Changes that could potentially occur through conventional breeding or natural genetic variation.

However, the absence of foreign DNA does not automatically establish that an edited organism is safe. Its characteristics, intended use and possible environmental effects must also be considered.

Major mechanisms of fast-track approval

1. Exemption-based regulatory pathway

Under this approach, certain genome-edited organisms are exempted from the full regulatory framework applicable to conventional genetically modified organisms.

The exemption generally depends on the type of genetic modification and whether foreign genetic material is present.

2. Simplified risk assessment

Low-risk products may undergo a proportionate assessment focusing on relevant biological characteristics rather than the complete testing requirements applicable to higher-risk products.

3. Regulatory notification

Developers may be required to submit information describing the genetic modification, the organism involved and the intended application.

The regulatory authority evaluates whether the product qualifies for simplified treatment.

4. Reduced approval timelines

Fast-track mechanisms may provide shorter review periods, simplified documentation and clearer administrative procedures.

5. Post-approval monitoring

Even when a product receives simplified approval, monitoring may be required where potential environmental or agricultural risks remain.

International legal and regulatory framework

1. United States – SECURE Rule, 2020

The United States Department of Agriculture (USDA) introduced the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule under its biotechnology regulations.

The framework provides exemptions for certain modified plants that could otherwise have been developed through conventional breeding or that satisfy specified regulatory conditions.

It establishes a risk-based approach to regulating certain genetically engineered plants.

The SECURE Rule is important because it distinguishes certain low-risk genome-edited plants from other genetically engineered organisms requiring more extensive regulatory review.

2. European Union regulatory framework

The European Union traditionally regulates genetically modified organisms under Directive 2001/18/EC.

In Confédération paysanne v. Premier ministre (2018), the Court of Justice of the European Union clarified that organisms obtained through newer mutagenesis techniques generally fall within the GMO regulatory framework, subject to the applicable exception for techniques with a long history of safe use.

The European Commission subsequently proposed a separate regulatory framework for certain new genomic techniques in plants in 2023.

This proposal sought to establish different regulatory categories, including simplified requirements for certain plants considered comparable to conventional varieties.

3. United Kingdom – Genetic Technology (Precision Breeding) Act, 2023

The United Kingdom introduced the Genetic Technology (Precision Breeding) Act, 2023, to establish a distinct regulatory framework for qualifying precision-bred plants and animals in England.

The legislation distinguishes certain precision-bred organisms from conventional genetically modified organisms.

Its framework provides for notification, risk assessment and regulatory oversight rather than automatically applying the entire traditional GMO approval system.

4. International Cartagena Protocol on Biosafety, 2000

The Cartagena Protocol provides an international framework for the safe handling, transportation and use of living modified organisms.

Article 15 deals with risk assessment, while Article 16 addresses risk management.

The Protocol does not establish a universal fast-track approval system. However, its risk-assessment principles support scientifically proportionate regulatory decision-making.

Indian legal framework governing fast-track approvals

India has developed a specific regulatory approach for certain genome-edited plants through the existing biotechnology regulatory framework.

1. Environment (Protection) Act, 1986

The Act provides the legislative foundation for regulating genetically engineered organisms and protecting the environment.

2. Rules, 1989

The Rules regulate the manufacture, use, import, export and storage of hazardous microorganisms and genetically engineered organisms or cells.

They establish institutional and governmental oversight through bodies such as the Institutional Biosafety Committee (IBSC), Review Committee on Genetic Manipulation (RCGM) and Genetic Engineering Appraisal Committee (GEAC).

3. Guidelines for Safety Assessment of Genome Edited Plants, 2022

India's Department of Biotechnology issued the Guidelines for Safety Assessment of Genome Edited Plants in 2022.

These guidelines introduced a differentiated regulatory approach for certain genome-edited plants.

They establish two important categories:

SDN-1: Genome editing involving small deletions or insertions without introducing foreign DNA.

SDN-2: Genome editing involving targeted changes using a DNA repair template, without introducing foreign DNA into the final plant.

Certain plants developed through SDN-1 and SDN-2 techniques are exempted from specified biosafety assessment requirements applicable under the Rules, 1989, subject to the conditions and procedures in the guidelines.

4. Genetic Engineering Appraisal Committee (GEAC)

GEAC performs an important regulatory role in evaluating genetically engineered organisms and relevant environmental release proposals.

The simplified regulatory pathway for qualifying genome-edited plants does not mean that all genome-edited products automatically receive approval. Developers must establish eligibility and follow the applicable regulatory procedure.

Important case laws

1. Confédération paysanne v. Premier ministre (2018)

The Court of Justice of the European Union examined whether organisms produced through newer mutagenesis techniques, including certain genome-editing methods, should be treated as genetically modified organisms under European law.

The Court held that organisms obtained through mutagenesis techniques developed after the adoption of the relevant GMO legislation generally fell within the scope of GMO regulation.

It also recognised an exception for organisms obtained through techniques that have conventionally been used in a number of applications and have a long history of safety.

Legal significance: The judgment established that newer genome-editing techniques cannot automatically escape GMO regulation merely because they do not involve the introduction of foreign DNA. It is particularly important when determining eligibility for simplified regulatory pathways.

2. R (Quintavalle) v. Secretary of State for Health (2003)

The House of Lords examined whether embryos created through cell nuclear replacement technology fell within the statutory definition of embryos under the Human Fertilisation and Embryology Act, 1990.

The Court adopted an interpretation that accommodated scientific developments within the existing legal framework.

Legal significance: The judgment demonstrates that biotechnology legislation must be interpreted in light of scientific progress. It supports the need for adaptable regulatory frameworks for emerging genetic technologies.

3. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

The Supreme Court of India examined disputes involving Monsanto's Bt cotton technology and licensing arrangements with Indian seed companies.

The dispute primarily concerned intellectual property protection and the legal status of biotechnology-related inventions.

Legal significance: The judgment highlights the relationship between biotechnology innovation, intellectual property protection and agricultural regulation. It is relevant to the commercial environment in which fast-track genome-editing approvals operate.

4. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court of India recognised the precautionary principle as an important component of environmental law.

The Court emphasised the need to adopt preventive measures where activities may create environmental risks.

Legal significance: The precautionary principle is relevant to fast-track biotechnology approvals because simplified procedures must not eliminate necessary scientific assessment or environmental safeguards.

Advantages of fast-track approvals

1. Faster scientific innovation: Simplified procedures allow researchers to move eligible low-risk products through regulatory assessment more efficiently.

2. Reduced development costs: Smaller regulatory burdens may reduce costs for universities, agricultural research institutions and biotechnology companies.

3. Agricultural productivity: Genome-edited crops may provide improved resistance to diseases, environmental stress and certain agricultural challenges.

4. Greater research participation: Simplified pathways may encourage smaller research institutions and biotechnology startups to participate in agricultural innovation.

5. International competitiveness: Efficient regulatory frameworks may help countries develop competitive agricultural biotechnology sectors.

Challenges and legal concerns

Despite their advantages, fast-track approvals create several important challenges.

Definition of low risk: There is no universally accepted definition of a low-risk genome edit.

Scientific uncertainty: Small genetic changes may still produce unexpected biological effects.

Regulatory differences: Countries follow different approaches to genome-edited organisms, creating international trade difficulties.

Transparency: Consumers and farmers may demand information about the genetic characteristics of edited crops.

Environmental protection: Simplified approval should not undermine biodiversity conservation.

Intellectual property disputes: Genome-editing technologies may involve overlapping patent and plant variety protection rights.

Public acceptance: Differences in public attitudes towards genetic modification may influence the adoption of edited crops.

Recommendations for an effective fast-track approval framework

An effective regulatory system should include:

Clear scientific criteria for identifying low-risk edits.

Simplified but transparent notification procedures.

Independent scientific evaluation where necessary.

Appropriate exemptions for qualifying low-risk products.

Mandatory documentation of genetic modifications.

Proportionate post-release monitoring.

Coordination between biotechnology and environmental authorities.

Public access to relevant regulatory information.

Periodic review of approval criteria as scientific knowledge develops.

Conclusion

Fast-track approvals for low-risk genome edits represent an important development in modern biotechnology regulation. They provide a mechanism for encouraging scientific innovation while ensuring that regulatory requirements remain proportionate to potential risks.

International approaches such as the United States SECURE Rule and the United Kingdom's Genetic Technology (Precision Breeding) Act, 2023, demonstrate the movement towards differentiated regulation of certain genome-edited products.

In India, the Guidelines for Safety Assessment of Genome Edited Plants, 2022, provide an important framework for qualifying SDN-1 and SDN-2 genome-edited plants.

Judicial decisions such as Confédération paysanne v. Premier ministre and Vellore Citizens' Welfare Forum v. Union of India demonstrate the importance of clear regulatory classification, scientific assessment and precautionary safeguards.

Ultimately, fast-track approval systems should encourage biotechnology development without compromising environmental protection, food safety, transparency and public confidence.